Ontario Teachers Pension Plan Board Grows Stock Position in Merck & Co., Inc. (NYSE:MRK)

Ontario Teachers Pension Plan Board increased its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 4.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 29,316 shares of the company’s stock after buying an additional 1,252 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Merck & Co., Inc. were worth $3,196,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Richwood Investment Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 1.1% during the 4th quarter. Richwood Investment Advisors LLC now owns 16,816 shares of the company’s stock valued at $1,833,000 after buying an additional 190 shares during the period. Barry Investment Advisors LLC increased its holdings in Merck & Co., Inc. by 1.0% during the 4th quarter. Barry Investment Advisors LLC now owns 12,911 shares of the company’s stock worth $1,418,000 after purchasing an additional 124 shares during the last quarter. JPL Wealth Management LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $1,534,000. Central Valley Advisors LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $1,729,000. Finally, InterOcean Capital Group LLC grew its position in shares of Merck & Co., Inc. by 8.2% in the 4th quarter. InterOcean Capital Group LLC now owns 14,011 shares of the company’s stock worth $1,527,000 after acquiring an additional 1,059 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Berenberg Bank lifted their target price on Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. TheStreet lowered Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. UBS Group lifted their target price on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 27th. Finally, Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective for the company. in a research report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $131.33.

Get Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Up 0.0 %

NYSE:MRK traded up $0.02 during trading hours on Thursday, hitting $131.12. 1,894,006 shares of the company’s stock traded hands, compared to its average volume of 7,948,738. The firm has a market cap of $332.10 billion, a P/E ratio of 145.67, a P/E/G ratio of 1.67 and a beta of 0.39. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $133.10. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. The stock’s fifty day moving average price is $127.78 and its two-hundred day moving average price is $119.31.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.21 billion. During the same quarter in the previous year, the company posted $1.40 earnings per share. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, research analysts expect that Merck & Co., Inc. will post 8.69 earnings per share for the current fiscal year.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.